Moxifloxacin-Induced Peripheral Neuropathy: A Rare Side Effect of Fluoroquinolone Therapy in Tuberculosis Management
Abstract
Moxifloxacin (MXF) is a cornerstone of the newly recommended four-month 2HPMZ/2HPM regimen for drug-susceptible pulmonary tuberculosis (TB). However, potential side effects such as cumulative neurotoxicity remain poorly characterized in clinical practice. Here, we report a rare case of peripheral neuropathy (PN) occurring after 17 weeks (four months) of MXF treatment in a 60-year-old Vietnamese man treated for drug-sensitive pulmonary TB. Following early isoniazid-induced hepatotoxicity, the patient's regimen was modified to include MXF 400 mg daily, notably without other neurotoxic agents such as linezolid or ethambutol. After 17 weeks of MXF therapy, the patient developed symmetrical stocking-glove PN. Extensive workup, including hemoglobin A1c and folate levels, ruled out common metabolic and nutritional etiologies. Cessation of MXF and pyridoxine supplementation led to gradual symptom improvement with full resolution after four months. While FDA warnings emphasize the often-rapid onset of fluoroquinolone-associated nerve damage within days of initiation, this case illustrates a delayed, cumulative toxicity profile that aligns with recent epidemiological evidence. As global TB guidelines shift toward four-month MXF regimens, this report highlights a critical safety consideration for clinicians and the importance of routine neurological screening throughout the entire treatment course to detect early signs of toxicity and prevent the development of potentially permanent PN.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.